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A casual observer of retinoid research over the past five years could be forgiven for thinking that the role of retinoic acid , a derivative of vitamin A (retinol), in tissue development and maintenance is close to being understood. Yet, despite the tremendous advances in 
characterizing at least one mechanism of action of retinoic acid, that 
of its role in transcriptional regulation via the nuclear retinoic acid 
receptors (RARs) and retinoid X receptors (RXRs), we are still far 
from understanding how changes in intracellular concentrations of 
this molecule are regulated during development and how con-
sequential effects at the level of single genes or sets of genes deter-
mine cell phenotype. Since the identification of 9-cis retinoic acid 
as the ligand for RXRs and an additional ligand for RARs, ex-
perimental evidence i.ncrea.singly favors RAR~~R h~terodimers as 
mediators of some bIOlogIC responses to retlllolC aCid. More than 
ever, we need to understand the mechanism and regulation of 
transfer of retinol into cells, the factors that regulate the synthesis of 
retinoic acid from retinol, and the mechanisms by which intracellu-
lar levels of the all-trans and 9-cis isomers of retinoic acid are regu-
lated. 
Dermatology is one discipline that is leading the way in retinoid 
research, driven by the tremendous potential of retinoids for treat-
ing acne, deskeratotic diseases, photodamage, and skin cancer. In 
recent years, John Voorhees' group at the University of Michigan 
has made major contributions to the cellular and molecular biology 
of retinoids in human skin. Another paper from his laboratory, by 
Christopher Griffiths and coll eagues in the September 1993 issue (j 
Illvest Dermatol 101:325 - 328, 1993), highlights some important 
issues concerning the mechanism of the therapeutic effects of reti-
noids and the properties of retinoid analogues. 
Griffiths et al [1] have compared the effects of all-trailS retinoic 
acid and CD271, a retinoic acid analogue, on human skin morphol-
ogy and histology. Normal buttock skin treated with retinoic acid, 
CD271, or appropriate vehicle under occlusion for 4 d has been used 
as the experimental model. Their main conclusion is that CD271, 
when used at doses effective in the treatment of acne, produces few 
of the morphologic and histologic changes obtained with retinoic 
acid treatment, but, like retinoic acid, does result in a significant 
increase in expression of mRNA coding for cellular retinoic acid-
binding protein-II (CRABP-II). 
The CRABP-II gene promoter has sequences representing reti-
noic acid response elements (RAREs) to which RARs bind in a 
ligand-dependent manner, resulting in an induction of CRABP-II 
transcription. The CRABP-II RARE elements, of which there are 
two, preferentially bind RAR-RXR heterodimers [2]. RARs can 
bind all-trailS retinoic acid and 9-cis retinoic acid with apparently 
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1993. 
similar affinity, whereas RXRs bind only 9-cis retinoic acid [2). 
Induction of CRABP-II expression by retinoic acid in skin is there-
fore presumably RAR-mediated, but all-trm'l5 retinoic acid may iso-
merise ill vivo to give 9-cis retinoic acid for binding to a heterodimer 
RXR partner. The potential contribution of RXRs to CRABP-II 
induction in skin can, so far, only be inferred from transfection 
experiments [2], and the extent to which CRABP-II induction in 
skin is dependent on the binding of 9-cis retinoic acid to RXRs is 
also unknown. III llitro, at least, CRABP-II induction by retinoic 
acid is more effective if all-traIlS and 9-cis retinoic acid are used 
together [2). CD271 is a structural analogue of all-trailS retinoic acid 
[3] and the fact that it also induces CRABP-II expression in human 
skin raises the question whether CD271 has any binding affinity 
for RXRs, and, if not, whether RXRs participate in CRABP-II 
induction by CD271 and require endogenous 9-cis retinoic 
acid. 
The fact that CD271 is therapeutically effective at doses capable 
of inducing CRABP-II but which do not induce the morphologic 
and histologic changes characteristic of high doses of all-trailS reti-
noic acid [1) implies that the therapeutic properties of CD271 may 
be mediated, like CRABP-II induction, by an RAR-dependent 
mechanism. If, as the authors hope, the induction of CRABP-II 
turns out to be a sensitive marker for the potential therapeutic ef-
fects of retinoic acid, this suggests the exciting possibility that a 
combination of CD271 with a stable analogue of9-cis retinoic acid 
might have considerable therapeutic potential. Alternatively, be-
cause 9-cis retinoic acid binds to RARs with a similar affinity to 
all-traIlS retinoic acid, stable analogues or 9-cis retinoic acid could be 
more potent than all-trans retinoic acid analogues in the treatment 
of some skin diseases. However, one thing is certain: we need to 
know much more about the mechanism of retinoic acid in counter-
acting disease and the role of different classes of nuclear receptors 
such as RARs and RXRs. 
The affinity of CD271 for RARs is 10- 80 times lower than 
all-tra rls retinoic acid [4) and this means that when equal doses of 
CD271 and all-trans retinoic acid are compared, the effective dose of 
CD271 may in fact be equivalent to a much lower dose of all-trans 
retinoic acid. This could explain why Griffiths et al [1) found that 
CD271 had little effect on proliferation, skin morphology, and 
histology; as the authors point out, low concentrations of all-traIlS 
retinoic acid also lack these effects yet still induce expression of 
CRABp-II. Nevertheless, a comparison between low concentra-
tions of all-trailS retinoic acid and CD271 at the dose used in this 
study may not be that simple. 
One interpretation of the fact that all-trailS retinoic acid induces 
skin hyperplasia and has morphologic and histologic effects at high 
doses is that these effects require the presence of retinoic acid over a 
relatively long period. Given chat retinoic acid may be rapidly me-
tabolized, a biologically effective level of retinoic acid may only be 
sustainable from a single application by using a high initial dose. 
However, if, as may be the case with CD271, biologically effective 
levels of a retinoid analogue can be sustained without appreciable 
metabolism yet without causing hyperplasia or other morphologic 
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changes, this would imply that these effects of retinoids on skin 
actually require high doses of retinoid and may be mediated by 
mechanisms other than through RARs and RXRs. To dissociate the 
toxic or irritant effects of retinoids from their therapeutic effects on 
cell differentiation has been a major aim of pharmaceutical compa-
nies for a number of years. T wo routes to achieve this aim are to 
modify retinoid structure to either remove the toxicity associated 
with high doses, or to make the molecule much more stable so that 
biologically effective doses can be maintained for longer. Because 
biologic potency seems to correlate well with affinity for RARs but 
not with affinity for CRABP [5], the use of stable retinoid analogues 
that can be used at sub-toxic doses may prove to be a more effective 
approach. C learl y, we need to know more about the metabolism of 
retinoids and retinoid analogues. Molecular techniques as illustrated 
by Griffiths el al [1] can be used as sensitive assays of response to 
retinoid analogues and the starting point of clinical studies to deter-
mine the molecular mechanism responsible for the therapeutic ef-
fects of these drugs. 
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